Search

Your search keyword '"Philip A. Read"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Philip A. Read" Remove constraint Author: "Philip A. Read"
38 results on '"Philip A. Read"'

Search Results

2. Chronic Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Is Associated With Sustained Protection Against Ischemic Left Ventricular Dysfunction in a Pilot Study of Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

3. Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies

4. Coronary collaterals provide a constant scaffold effect on the left ventricle and limit ischemic left ventricular dysfunction in humans

5. Targeted Left Ventricular Lead Placement to Guide Cardiac Resynchronization Therapy

6. Cardiac Resynchronization Therapy Optimization Using Noninvasive Cardiac Output Measurement

7. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

8. Impact of VV optimization in relation to left ventricular lead position: an acute haemodynamic study

9. The Impact of the Right Ventricular Lead Position on Response to Cardiac Resynchronization Therapy

10. Stunning and Cumulative Left Ventricular Dysfunction Occurs Late After Coronary Balloon Occlusion in Humans

11. Non-invasive cardiac output measurements based on bioreactance for optimization of atrio- and interventricular delays

12. Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization

13. TCT-214 GLP-1 cardioprotection against ischemic dysfunction in humans is not mediated by a mitochondrial K-ATP dependent pathway in left ventricular conductance catheter studies

14. 7 GLP-1 cardioprotection is not mitochondrial K-ATP channel dependent

15. CHRONIC DPP-4 INHIBITION BY SITAGLIPTIN IMPROVES GLOBAL MYOCARDIAL FUNCTION DURING DOBUTAMINE STRESS IN TYPE 2 DIABETES MELLITUS AND CORONARY ARTERY DISEASE

16. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial

17. Cardiac resynchronization therapy optimization using noninvasive cardiac output measurement

18. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

19. ACUTE NON-INVASIVE CARDIAC OUTPUT MEASUREMENTS FOLLOWING CARDIAC RESYNCHRONIZATION THERAPY PREDICT LEFT VENTRICULAR REVERSE REMODELING AT 6 MONTHS AND LONG TERM SURVIVAL

20. TARGETED LEFT VENTRICULAR LEAD PLACEMENT USING SPECKLE TRACKING ECHOCARDIOGRAPHY IMPROVES THE ACUTE HEMODYNAMIC RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY: A RANDOMIZED CONTROLLED TRIAL

21. The impact of the right ventricular lead position on response to cardiac resynchronization therapy

22. THE IMPACT OF RIGHT VENTRICULAR LEAD POSITION ON RESPONSE TO CARDIAC RESYNCHRONISATION THERAPY IN PATIENTS WITH CONCORDANT AND DISCORDANT LEFT VENTRICULAR LEADS

23. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

24. Effect of low-amplitude two-dimensional radial strain at left ventricular pacing sites on response to cardiac resynchronization therapy

25. Stunning and cumulative left ventricular dysfunction occurs late after coronary balloon occlusion in humans insights from simultaneous coronary and left ventricular hemodynamic assessment

26. New Perspectives in Treatment with Monoamine Oxidase Inhibitors

27. TCT-318 Cardioprotection with Glucagon-like Peptide-1 (GLP-1) may occur independent of coronary collaterals and metabolic substrate utilisation

29. 135 Chronic DPP-4 inhibition by sitagliptin enhances both global and regional myocardial function during dobutamine stress in patients with type 2 diabetes mellitus and coronary artery disease

31. 139 How important is the right ventricular lead position in patients undergoing cardiac resynchronisation therapy?

32. 086 Going beyond segmental timing alone to predict response to cardiac resynchronisation therapy: evaluation of a novel radial strain dyssynchrony index

33. 049 Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease: Abstract 49 Table 1

34. INFUSION OF GLUCAGON-LIKE PEPTIDE-1 PROTECTS AGAINST ISCHEMIC LEFT VENTRICULAR DYSFUNCTION DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY IN PATIENTS WITH CORONARY ARTERY DISEASE

35. THE RELATIONSHIP BETWEEN THE PROXIMITY OF LEFT VENTRICULAR LEAD POSITIONS TO THE LATEST SITE OF ACTIVATION AND RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY: HOW CLOSE DO YOU NEED TO BE?

36. Ultralinear Cathode Follower

37. Calculations of the Energy and Mass Yields from the Thermal-Neutron Fission ofU235

38. SITAGLIPTIN IMPROVES REGIONAL MYOCARDIAL FUNCTION DURING DOBUTAMINE STRESS IN TYPE 2 DIABETES MELLITUS AND CORONARY ARTERY DISEASE

Catalog

Books, media, physical & digital resources